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Abstract Autotaxin (ATX), an exo-nucleotide pyrophosphatase
and phosphodiesterase, stimulates tumor cell motility at sub-
nanomolar levels and augments invasiveness and angiogenesis.
We investigated the role of G protein-coupled phosphoinositide 3-
kinase Q (PI3KQ) in ATX-mediated tumor cell motility stimula-
tion. Pretreatment of human melanoma cell line A2058 with
wortmannin or LY294002 inhibited ATX-induced motility. ATX
increased the PI3K activity in p110Q, but not p85, immunopre-
cipitates. This effect was abrogated by PI3K inhibitors or
inhibited by pertussis toxin. Furthermore, stimulation of tumor
cell motility by ATX was inhibited by catalytically inactive form
of PI3KQ, strongly indicating the crucial role of PI3KQ for ATX-
mediated motility in human melanoma cells ß 2002 Federation
of European Biochemical Societies. Published by Elsevier Sci-
ence B.V. All rights reserved.
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1. Introduction
Cell motility is a fundamental process required during nor-
mal embryonic development, in£ammatory responses, wound
healing, and tumor metastasis [1]. Many types of tumor cells
have been found to produce ‘autocrine motility factors’ which
stimulate motility of the same tumor cells that make the factor
[2]. Autotaxin [ATX; nucleotide-pyrophosphatase phospho-
diesterase-2 (NPP-2)] is a 125-kDa glycoprotein initially iso-
lated from the human melanoma cell line A2058. This auto-
crine motility factor stimulates pertussis toxin (PTx)-sensitive
chemotaxis in human melanoma cells at picomolar to nano-
molar concentrations [3]. DNA sequence analysis determined
that ATX was homologous to a family of exo/ecto NPPs that
includes the B cell activation marker, PC-1, and the neural
di¡erentiation antigen, B10 [4]. Like other members of the
NPP family, ATX has multiple enzymatic activities [5]. The
phosphodiesterase (PDE) activity appears to be essential for
motility stimulation, since a single point mutation at threo-
nine-210 abolishes the PDE- and tumor cell motility-stimulat-
ing activities of ATX [6].
A recent study has revealed that combination of ATX ex-
pression with ras transformation produced cells with greatly
ampli¢ed tumorigenesis and metastatic potential compared to
ras-transformed controls. Thus, ATX appears to augment cel-
lular characteristics necessary for tumor aggressiveness [7].
Furthermore, ATX stimulates HUVECs grown on Matrigel
to form tubules, much like vascular endothelial growth factor
[8], suggesting that ATX could contribute to the metastatic
cascade through multiple mechanisms.
Recently, accumulating evidences suggest that various intra-
cellular signaling molecules such as phosphoinositide 3-kinase
(PI3K) [9], phospholipase CQ (PLCQ) [10], mitogen-activated
protein kinase [11], and protein kinase C [12] were di¡eren-
tially involved in the stimulation of motility depending on
kinds of chemoattractants and cellular systems. Although
ATX has been demonstrated to act as a autocrine motility
factor in tumor cells [3], little is known about the signaling
mechanism by which ATX stimulates cell motility. Therefore,
the clari¢cation of the possible involvement of speci¢c signal-
ing molecule in ATX stimulation of motility would be impor-
tant for understanding the molecular mechanisms of tumor
invasion and metastasis.
In the present study, we investigated the possible involve-
ment of PI3K on ATX-induced tumor cell motility stimu-
lation and found that G protein-coupled PI3KQ plays a piv-
otal role in the stimulation of motility by ATX in human
melanoma cells.
2. Materials and methods
2.1. Reagents
Wortmannin and LY294002 were from Sigma. PTx was purchased
from Calbiochem (San Diego, CA, USA). Anti-PI3K p110Q and p85
antisera were purchased from Santa Cruz Technology (Santa Cruz,
CA, USA). [Q-32P]ATP was from Amersham (Piscataway, NJ, USA).
All reagents from commercial sources were of analytical grade.
2.2. Cell culture
The human melanoma cell line A2058, originally isolated from To-
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daro et al. [9], was maintained as described previously [10]. The cells
were maintained at 37‡C in Dulbecco’s modi¢ed Eagle’s medium
(DMEM) with 10% fetal bovine serum (complete medium) in a hu-
midi¢ed 5% CO2. For analysis of ATX-induced signals, cells in ex-
ponential growth were washed extensively to remove growth factors
and resuspended in serum-free media (basal media) for 6 h to induce
maximum synchronization.
2.3. Expression plasmid and transfection
pcDNA3 expressing the catalytically inactive mutant of PI3KQ with
isoprenylation signal of K-Ras, PI3KQK832R, was kindly provided by
M. Wymann (Institute of Biochemistry, University of Fribourg) and
are described elsewhere [11,12]. Human melanoma cells were transi-
ently transfected with pcDNA3 vector or PI3KQK832R plasmid using
SuperFact1 transfection system (Qiagen). 25 Wl of SuperFact1 trans-
fection reagent was added to 5 Wg of plasmid and incubated at room
temperature for 10 min. After adding 1 ml of complete medium, DNA
and transfection reagent mix were added to 2U105 cells per 60 mm
dish and incubated for 3 h at 37‡C in a humidi¢ed 5% CO2. Cells were
washed with PBS and grown in complete medium for 48 h before cell
motility assays.
2.4. Puri¢cation of recombinant ATX
ATX cDNA, which included the full-length open reading frame,
was subcloned into the plasmid vector pcDNA3 (Invitrogen) and
then transiently transfected into Cos-1 cells using the DEAE^dextran
method [13]. Control for these experiments was Cos-1 cells which had
been transfected with empty pcDNA3 vector. After overnight recov-
ery in complete medium, DMEM containing 0.1 mg/ml bovine serum
albumin was added to the cells, harvested after 48 h, and concen-
trated. The concentrated supernatants from both atx-transfected
and control Cos-1 cells were partially puri¢ed by lectin a⁄nity chro-
matography with concanavalin A-agarose (Vector Laboratories) as
described previously in detail [6], and both puri¢ed fractions were
used as stimulator and control for unstimulated experiment, respec-
tively.
2.5. PI3K activity assay in vitro
PI3K activity was assayed essentially as described previously [14]
with some minor modi¢cations. 500 Wg of protein from each sample
was immunoprecipitated with 1 Wg of anti-p110Q or anti-p85 antibody
for 90 min at 4‡C. Immunoprecipitates were rinsed and then incu-
bated with 0.5 mg/ml phosphoinositols (PtdIns) and 20 WCi of [Q-
32P]ATP in reaction bu¡er (50 WM ATP, 10 mM MgCl2, 20 mM
HEPES, pH 7.5) for 30 min at 30‡C. The lipid products were ex-
tracted by methanol/chloroform and separated in thin-layer chroma-
tography (TLC). Phosphorylated products were detected by Fluores-
cent Image Analyzer FLA2000 (Fuji¢lm, Japan).
2.6. Reverse transcription-polymerase chain reaction (PCR) of human
melanoma cell p110Q
Total RNA from human melanoma cells, A2058, was isolated using
TriZol (Life Technologies, Inc.) following the manufacturer’s
suggested protocols and reverse transcription-PCR was assayed
essentially as described previously [15] with some modi¢cation. The
primer sequences for p110Q and GAPDH are as follows: sense1,
GTGGTGCTGAGAGAGGACAA, antisense1, CTATCAGCAGCA-
GGTTCACA (1.38-kb fragment); sense2, ACAGATTCTACGAA-
TCATGG, antisense2, GCATTCCTGTCATCAGCATC (0.585-kb
fragment); GAPDH sense, GACCCCTTCATTGACCTCAA, GAP-
DH antisense, CATGGACTGTGGTCATGAGC. The sequence of
PCR ampli¢cation was one cycle of denaturation at 95‡C for 5 min
followed by annealing at 56‡C for 30 s and extension at 72‡C for
1 min. This cycle was followed by 30 s at 95‡C, 30 s at 56‡C, and
1 min at 72‡C, repeated 38 times. The PCR reaction was sampled
every ¢ve cycles from cycle 25 to 40, inclusively. The samples were
separated on a 2% agarose gel, stained with ethidium bromide, and
compared for intensity.
2.7. Immunoblotting
A2058 cells were washed with ice-cold PBS and lysed in lysis bu¡er
(50 mM Tris^HCl, pH 7.4, 1% Nonidet P-40, 150 mM NaCl, 1 mM
EDTA, 1 mM phenylmethylsulfonyl £uoride, 1 Wg/ml aprotinin and
leupeptin, 1 mM sodium orthovanadate, and 1 mM NaF). Proteins
were separated on SDS^polyacrylamide gel electrophoresis (10%) and
electrophoretically transferred to polyvinylidene di£uoride mem-
branes. Membranes were blocked for 30 min in PBS containing
0.1% Tween 20 (PBS-T) and 5% (w/v) dry skim milk powder, and
incubated overnight with anti-p110Q. The membranes were then
washed with PBS-T and incubated for 1 h with an anti-rabbit second-
ary antibody. Bound antibodies were detected with the enhanced am-
pli¢ed alkaline phosphatase immunoblot system (Bio-Rad).
2.8. Cell motility assays
Motility assays were performed in triplicate using a 48-well micro-
chemotaxis chamber for 4 h as described previously in detail [3]. In
brief, A2058 melanoma cells that were approximately 75^90% con£u-
ent were harvested with trypsin-EDTA and allowed to recover at
room temperature in DMEM supplemented with 10% heat-inactivated
fetal bovine serum for at least 1 h. The cells were then resuspended at
2U106 cells/ml in DMEM with 1 mg/ml bovine serum albumin. Gel-
atin-coated Nuclepore membranes used in these modi¢ed Boyden
chambers were ¢xed and stained using Di¡-Quik reagents (American
Scienti¢c Products). Chemotaxis was quanti¢ed densitometrically us-
ing EagleSight Software v. 3.2 (Stratagene) for data analysis as de-
scribed previously [16].
3. Results and discussion
Dysregulation of motility plays an important role in pro-
moting invasion and metastasis [17]. Cytokines and growth
factors stimulate tumor cell motility through various intracel-
lular signaling molecules including PI3K [18], PLCQ [19], mi-
togen-activated protein kinase [20], and protein kinase C [21].
Recently, ATX was reported as a metastasis-enhancing mito-
m
m
Fig. 1. E¡ects of PI3K inhibitors on ATX-mediated tumor cell mo-
tility. Cells were treated with various concentrations of wortmannin
(A) or LY294002 (B) for 30 min before motility assays against
ATX or control. Data shown are the densitometric values with the
mean þ S.D. of three separate experiments, and motility assay was
carried out in triplicate experiments.
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gen and angiogenic factor without any knowledge about intra-
cellular signaling pathway [7,8]. To identify the factor that
mediates the ATX-induced tumor cell motility, we ¢rst exam-
ined PI3K as a candidate of ATX signaling molecule by uti-
lizing the PI3K inhibitors, wortmannin and LY294002. A2058
cells were incubated with various concentrations of each in-
hibitors for 30 min, then assayed for their motility response to
ATX. As shown in Fig. 1A,B, both PI3K inhibitors blocked
the ATX-mediated tumor cell motility stimulation in a dose-
dependent manners, indicating the possible involvement of
PI3K in the stimulation of tumor cell motility by ATX.
Four mammalian type I PI3K isoforms (p110K, L, Q, N)
have been identi¢ed [22]. The type IA PI3Ks, p110K, p110L
and p110N, associate with the p85 family of regulatory sub-
units, but type IB p110Q binds to a p101 adaptor molecule
[12,23]. Whereas type IA PI3Ks are activated by interaction
with tyrosine-phosphorylated molecules, p110Q is regulated
preferentially by interaction with heterotrimeric G protein
subunits [23]. The presence of p110Q was described in human
neutrophil [15], NK cells [24], T lymphocytes [25], and vascu-
lar smooth muscle cell nuclei [26]. To test whether human
melanoma cells express p110Q, we utilized PCR ampli¢cation
with oligonucleotide primers that are speci¢c for human
p110Q. As shown in Fig. 2A, the results revealed fragments
of the expected sizes of 1377 and 585 bp. Similarly, immuno-
blots of cell lysates, performed with polyclonal antibody
against p110Q, revealed that this antibody detected a protein
band at an approximate molecular mass of 110 kDa. Thus,
A2058 cells appear to express both mRNA and protein for
p110Q (Fig. 2A,B).
Since Gi protein appears to be involved in ATX-mediated
tumor cell motility stimulation [3], we then determined
whether p110Q is activated by ATX. A2058 cells were incu-
bated for various times ranging from 15 s to 15 min with 250
ng/ml ATX. The treated cells were lysed and immunoprecipi-
tated with anti-p110Q antibody, and PI3K activities in the
immunoprecipitates were assayed. As shown in Fig. 3A,
ATX treatment resulted in increased formation of phosphati-
dylinositol 3-phosphate [PtdIns(3)P] from PtdIns. This in-
crease began as early as 15 s after stimulation with ATX
and continued for at least 15 min. The increased production
of PtdIns(3)P was abrogated when the cells had been preincu-
bated with either 500 nM wortmannin or 10 WM LY294002
before ATX stimulation (Fig. 3B). Upon preincubation for 90
min with PTx prior to ATX stimulation, ATX-induced
PtdIns(3)P production was decreased by 66% (Fig. 3B).
The e¡ect of ATX on type IA PI3Ks was tested in homol-
ogous experiments (Fig. 3A). A2058 cells were stimulated with
ATX (250 ng/ml) for 15 s to 15 min, lysed, and immunopre-
cipitated using an anti-p85 antibody. Unlike p110Q, ATX
treatment had no signi¢cant e¡ect on the production of
PtdIns(3)P by anti-p85 immunoprecipitates (Fig. 3A,B). This
result is in accordance with the complete inhibition of the
chemotactic factor-stimulated generation of PtdIns(3,4,5)P3,Fig. 2. Presence of p110Q in human melanoma cells. A: 10 Wg of to-
tal RNA puri¢ed from melanoma cells were reverse-transcribed and
subjected to PCR using primers designed from the published human
p110Q PI3K DNA sequence. GAPDH primers were included as a
positive control. Lane 1: Molecular weight markers (xX174 DNA-
HaeIII digest); lane 2: GAPDH; lane 3: 1377 bp DNA fragment of
p110Q ; lane 4: 585 bp DNA fragment of p110Q. B: Cell lysate was
immunoblotted with the anti-p110Q antiserum. The results of these
experiments are typically representative of three separate experi-
ments.
Fig. 3. Activation of p110Q by ATX in A2058 cells. A: Stimulation
of the activity of p110Q by ATX in various times. After treatment
with 250 ng/ml ATX for the indicate times, cell lysates were sub-
jected to PI3K assay by immunoprecipitation using speci¢c antibody
against the p110Q or p85 as described under Section 2. B: E¡ects of
wortmannin, LY294002, and PTx on the stimulation of p110Q activ-
ity by ATX. After pretreatment with or without each reagents (0.5
WM wortmannin, 30 min; 10 WM LY294002, 30 min; 200 ng/ml
PTx, 90 min), ATX was treated for 300 s. The upper panel depicts
the result of a representative TLC plate and the lower panel shows
the average densitometric values. Data shown are the mean þ S.D.
from triplicate samples and are typically representative of three sep-
arate experiments.
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severe defects in migration in murine p110Q3=3 neutrophils
[27], and a reduced migration toward a wide range of chemo-
tactic stimuli in peritoneal PI3KQ-null macrophages [28]. Frac-
tions puri¢ed from the conditioned medium of empty vector-
transfected Cos-1 cells did not increase the p110Q activity
(data not shown).
To con¢rm the involvement of PI3KQ in signal transduction
of ATX, pcDNA3 vector alone or pcDNA3 expressing the
catalytically inactive mutant of PI3KQ, PI3KQK832R [11],
was transiently transfected into A2058 cells, and their motility
against ATX or control was monitored. As shown in Fig. 4,
tumor cell motility in cells transfected with empty vector was
increased up to a 3.9-fold in response to ATX, which is sim-
ilar to that of non-transfected cells (compare to Fig. 1). How-
ever, overexpression of PI3KQK832R led only to a 1.5-fold
increase in tumor cell motility by ATX, indicating that the
PI3KQ signal pathway is closely associated with ATX-medi-
ated tumor cell motility.
In conclusion, the present study provides the ¢rst evidence
that the G protein-coupled PI3K, p110Q plays an important
role in ATX-induced stimulation of motility in human mela-
noma cells. The role of PI3KQ in increased tumor cell invasion
and angiogenesis by ATX and downstream factors that may
be a¡ected by this activated PI3K are subjects of current in-
vestigation.
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Fig. 4. Involvement of PI3KQ in ATX-induced tumor cell motility.
pcDNA3 or pcDNA3 with PI3KQK832R was transiently transfected
into A2058 cells using SuperFact1 system and used for motility as-
say toward ATX or control. Data shown are the densitometric val-
ues with the mean þ S.D. of three separate experiments, and motility
assay was carried out in triplicate experiments.
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